Background -It has recently been reported that acetaldehyde induces bronchoconstriction indirectly via histamine release. However, no study has been performed to assess whether acetaldehyde worsens bronchial responsiveness in asthmatic subjects so this hypothesis was tested. Methods -Methacholine provocation was performed on three occasions: (1) after pretreatment with oral placebo and inhaled saline (P-S day), (2) after placebo and inhaled acetaldehyde (P-A day), and (3) after a potent histamine H, receptor antagonist terfenadine and acetaldehyde (T-A day) in a double blind, randomised, crossover fashion. Nine asthmatic subjects inhaled 0-8 mg/ml acetaldehyde or saline for four minutes. After each inhalation a methacholine provocation test was performed. Results -Methacholine concentrations producing a 20% fall in FEVI (PC20-MCh) on the P-A day (0-48 mg/ml, 95% CI 0-21 to 1P08) and T-A day (0-41 mg/ml, 95% CI 0-22 to 0 77) were lower than those on the P-S day (0 85 mg/ml, 95% CI 0-47 to 1-54). There was no change in the PC20-MCh between the P-A and T-A days. A correlation was observed between the logarithmic values of PC20-MCh (log PC20-MCh) on the P-S day and the potentiating effect of acetaldehyde on the methacholine responsiveness [(log PC20-MCh on P-A day) -(log PC20-MCh on P-S day)] (rho= 0 82). On the other hand, the severity of bronchial hyperresponsiveness correlates closely with the severity of symptoms,"'14 with the amount of treatment required to control symptoms,'5 and with the diurnal variation of airway function.'6 No study has been performed, however, to investigate the effect of acetaldehyde on bronchial responsiveness in asthmatic subjects.
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Conclusions -Acetaldehyde induces
bronchial hyperresponsiveness in patients with asthma by mechanisms other than histamine release.
lis-Menten constant (the substrate concentration at which an enzyme catalysed reaction proceeds at one half its maximum velocity) for aldehyde.1' About 50% of Japanese people lack the enzyme with a low Michaelis-Menten constant (ALDH 2) and show an elevation of serum acetaldehyde concentration due to their inability to metabolise acetaldehyde quickly and effectively."' It has been reported that ALDH 2 activity is a major determining factor of asthmatic exacerbations after drinking pure ethanol or alcoholic beverages in Japanese asthmatic subjects, and that changes in specific airway conductance are closely related to blood acetaldehyde levels. 2 We recently showed that inhaled acetaldehyde causes bronchoconstriction indirectly via histamine release in asthmatics,'2 and that the release of histamine made a major contribution to bronchoconstriction provoked after oral administration of alcohol (unpublished data). These findings suggest that acetaldehyde plays an important part in ethanol induced bronchoconstriction in Japanese subjects.
On the other hand, the severity of bronchial hyperresponsiveness correlates closely with the severity of symptoms,"'14 with the amount of treatment required to control symptoms, '5 and with the diurnal variation of airway function. '6 No study has been performed, however, to investigate the effect of acetaldehyde on bronchial responsiveness in asthmatic subjects.
We wished to determine (1) whether bronchial responsiveness to inhaled methacholine was altered when asthmatic subjects inhaled a subthreshold concentration of aerosolised acetaldehyde which did not cause bronchoconstriction per se, and (2) whether any increase in bronchial hyperresponsiveness after acetaldehyde was mediated by histamine release. 89-0 74-9 29-9 Sa = salbutamol via metered dose inhaler; Th = oral theophylline; FVC -forced vital capacity; FEV, -forced expiratory volume in one second; PC20-AcCHO = acetaldehyde concentration producing a 20% fall in FEV, consent was obtained from all subjects. This study was approved by the ethics committee of our hospital.
STUDY PROTOCOL
Non-specific bronchial responsiveness was measured on three occasions, each two weeks apart: (1) after pretreatment with oral placebo and inhaled saline (P-S day), (2) after placebo and inhaled acetaldehyde (P-A day), and (3) after a potent histamine H, receptor antagonist terfenadine and acetaldehyde (T-A day) in a double blind, randomised, crossover fashion. Terfenadine was given orally in a dose of 60 mg twice a day for three days and at 08.00 and 13.00 hours on the fourth (test) day. Placebo was administered by the same procedure as terfenadine. All medication, except for pretreatment with terfenadine and placebo, was stopped at 13.00 hours on the day before the test day to allow a washout time of at least 24 hours. The bronchial responsiveness to inhaled acetaldehyde was then measured at 15.00 hours on the test day.
AEROSOLISED ADMINISTRATION OF ACETALDEHYDE OR SALINE
An acetaldehyde concentration producing a 20% fall in FEV, (PC20-AcCHO) was determined as previously described'2 (table 1). Acetaldehyde was dissolved in physiological saline to make a solution of 0-8 mg/ml, the subthreshold concentration having no direct bronchoconstrictor effect itself in a preliminary study. Acetaldehyde and saline were inhaled from a DeVilbiss 646 nebuliser (DeVilbiss, Somerset, Pennsylvania, USA) opeated by compressed air at 5 1/min. The nebuliser output was 0 14 ml/min. Each solution was inhaled for four minutes by tidal breathing with the nebuliser while wearing a noseclip, and this was followed immediately by measurements of FEV,. MEASUREMENT stopped or postponed. Methacholine was inhaled for two minutes by tidal breathing and followed immediately by measurements of FEV,. Increasing concentrations of methacholine were inhaled until a fall of 20% or more in FEV, occurred. These values were plotted on semilogarithmic graph paper and a methacholine concentration producing a 20% fali in FEV, (PC20-MCh) was determined from the post saline FEV, value before the first inhalation of methacholine. FEV, was measured three times and the best value of three attempts was recorded each time.
DATA ANALYSIS FEVI data were expressed as mean and 95% confidence intervals (95% CI). Analysis of variance (ANOVA) was used for differences in baseline FEV, between the three test days. FEV, values and percentage changes in FEV, from the preinhalation value after inhalation of either acetaldehyde or saline were also analysed by ANOVA. PC20-MCh values were logarithmically transformed for analysis and reported as the geometric mean (95% CI). ANOVA followed by Fisher's protected least significant difference was used to analyse changes in PC20-MCh induced by treatment with acetaldehyde or saline. The degree of augmentation of methacholine responsiveness by acetaldehyde (APC20-MCh) was calculated as the difference between the logarithmic values of PC20-MCh on the P-A and P-S days, and the logarithmic value of PC20-MCh on the P-S day was used as the baseline bronchial responsiveness. Correlations were obtained using Spearman's non-parametric rank correlation. A value of p < 0-05 was accepted for statistical significance. Figure 3 Relation between logarithmic values of PC20-MCh (the provocative concentration of methacholine producing a 20% fall in FEV,) on P-S day and potentiating effect of acetaldehyde on methacholine responsiveness calculated by the difference in logarithmic values of PC20-MCh on P-A and P-S days. P-S day: after pretreatment with oral placebo and inhaled saline; P-A day: after pretreatment with oral placebo and inhaled acetaldehyde; rho= 0 82, p < 005.
Results
The morning after drinking aloholic beverages exacerbation of asthmatic symptoms is observed in some Japanese asthmatic patients. We have recently shown a significant correlation between the bronchial responsiveness to acetaldehyde and the bronchial responsiveness to methacholine,"2 which was reconfirmed in the present study (fig 2) , and that FEV, was not altered by acetaldehyde inhalation in healthy subjects. In the present study the degree of increased bronchial hyperresponsiveness induced by acetaldehyde was related to the baseline bronchial hyperresponsiveness (fig 3) . It suggests that bronchial hyperresponsiveness is a necessary precondition for the expression of bronchial hyperresponsiveness induced by acetaldehyde.
Four asthmatic subjects in our group had no history of alcohol induced asthma, and inhalation of acetaldehyde tended to increase bronchial responsiveness (p < 0 1). This effect may be non-specific, and may result in an elevation of serum acetaldehyde concentration due to the inability of ALDH 2 to play an important part in ethanol induced asthma. However, the small number of subjects in this study make it difficult to reach a firm conclusion.
In conclusion, the subthreshold concentration of acetaldehyde increases non-specific bronchial responsiveness in asthmatic subjects, and the acetaldehyde induced bronchial hyperresponsiveness observed in asthmatics may, in the future, help to guide more physiological studies that could define the mechanism of alcohol induced bronchial hyperresponsiveness.
